1Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [ J ] . Cancer, 2007, 109(1): 25-32.
2Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence [ J ] . Clin Cancer Res, 2007, 13(15):4429-4434.
3Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [ J ] . Lancet, 2003, 362(9381): 362-369.
4Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours [ J ] . Nature, 2000, 406(6797): 747- 752.
5Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [ J ] . Proc Natl Acad Sci USA, 2003, 100(14): 8418- 8423.
6Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy [J ] . Clin Cancer Res, 2005, 11(16): 5678- 5685.
7Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [ J ] . Clin Cancer Res, 2007, 13(8): 2329-2334.
8Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [ J ] . J Clin Oncol, 2008, 26(8): 1275-1281.
9Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [ J ] . Mod Pathol, 2006, 19(2): 264-271.
10Siziopikou KP, Ariga R, Proussaloglou KE, et al. The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: A promising candidate for epidermal growth factor receptor-targeted therapy? [ J ] . Breast J, 2006, 12(4): 360-362.
1Perou CM, Sorlie T, Eisen MB,et al. Molecular portrails of humanbreast tumore[J]. Nature,2000,406(6797) :747 -752.
2Bryan BB,Schnitt SJ,Collins LC. Ductl carcinoma in situ with bas-al -like phenotype: a possible precursor to invasive basal - likebreast cancer[ J]. Mod Pathol,2006,19(5) :617.
3William J, Irvin Jr, Lisa A, et al . What is triple negative breastcancer[J]? Eur J Cancer,2008 ,44( 18) :2799 -2805.
4Keam B,Im SA,Kim HJ,et aL Prognostic impact of clinicopathologicparameters in stage II/III breast cancer treated with neoadjuvant do-cetaxel and doxorubicin chemotherapy:Paradoxical features of the tri-ple negative breast cancer [ J ]. BMC Cancer,2007 ,7 :203 -210.
5Dent R,Hanna WM,Trudear M,et al. Pattern of metastatic spreadin triple - negative breast cancer [ J ]. Breast Cancer Res Treat,2009,115:423 -428.
6Dolle JM,Dating JR, White E,et al. Risk factors for triple - nega-tive breast cancer in women under the age of 45 years [ J]. CancerEpidemiol Biomarkers Perv,2009,18(4-) :1157.
7Lin NU,Vanderplas A,Hughes ME,et al. Clinicopathological fea-tures and sites of recurrence according to breast cancer subtype inthe National Comprehensive Cancer Network( NCCN) [ J]. J Clin0ncol,2009,27 :543.
8Nielsen TO,Hsu FD Jensen K,et aL Immunohistochemical and clinicalcharacterization of the basal - like subtype of invasive breast carcino-ma[J].Clin Cancer Res,2004,10( 16) :5367 -5374.
9Linderholra BK,Hellborg H,Johansson U,et al. Significantly higherlevels of vascular endothelial growth factor ( VEGF) and shortersurvival times for patients with primary operable triple - negativebreast cancer[ J ]. Ann Oncol,2009,20 (10) :1639 - 1646.
10Nofech - Moze S,Trudeau M,Kahn HK,et aL Patterns of recurrence inthe basal and non - basal subtypes of triple - negative breast cancers[J]. Breast Cancer Res Treat,2009,118(1) : 131 -137.
